





Compacted chromatin, hypermethylation




Cellular homeostasis

Open chromatin and hypomethylation




Tumorigenesis




Supplemental Fig S1. UMAPs of canonical cell types in each individual tumor sample. Refer to Fig 1d for aggregate figure.


A




B








C



D



Supplemental Fig S2. Tumor corticotroph lineage tracing analysis. **A.** CellRank and scVelo analysis of patient sample P2. **i.** scVelo velocities projected onto UMAP embedding of all cells in both tumor and normal compartments colored by cell type. **ii.** scVelo velocities projected onto UMAP embedding of tumor corticotrophs, normal corticotrophs, and folliculostellate cells (FSC). **iii.** UMAP of corticotrophs from tumor and normal compartments. Cells are colored by CellRank fate probabilities, which is the likelihood that a given cell will transition toward the terminal population. **iv.** CellRank identified initial cell states. **v.** CellRank identified terminal cell states. **vi.** Transition matrix showing the fate probabilities of each macrostate. **vii.** Relative expression of relevant genes in each macrostate plotted over latent time. **B.** CellRank and scVelo analysis of patient sample P1. scVelo velocities projected onto UMAP embedding of tumor corticotrophs, normal corticotrophs, and FSCs (left), scVelo velocities projected onto UMAP embedding of tumor and normal corticotrophs (center), scVelo velocities projected onto UMAP embedding of tumor and normal corticotrophs with cells colored by relative *PPP1R17* expression (center). **C.** CellRank and scVelo analysis of patient sample P3. scVelo velocities projected onto UMAP embedding of tumor corticotrophs and FSCs (left), scVelo velocities projected onto UMAP embedding of only corticotrophs (center), scVelo velocities projected onto UMAP embedding of corticotrophs with cells colored by relative *PPP1R17* expression (center). **D.** CellRank and scVelo analysis of patient sample P3. scVelo velocities projected onto UMAP embedding of tumor corticotrophs and FSCs (left), scVelo velocities projected onto UMAP embedding of only corticotrophs (center), scVelo velocities projected onto UMAP embedding of corticotrophs with cells colored by relative *PPP1R17* expression (center).




A**B**

Normal Pituitary




Adenoma

Adenoma with normal pituitary




H&E




H&E



PPP1R17




Supplemental Fig S3. PPP1R17 expression is confined to CD adenomas. **A.** Multiplex immunohistochemistry of CD adenoma and surrounding normal pituitary gland (i) showing PPP1R17 expression (green) compared to corticotroph-specific POMC expression (red). PP2Ac expression (purple) staining is compared to PPP1R17 staining within the adenoma (iii–v). Scale bar = 50μM. **B.** Representative H&E of normal pituitary gland and CD adenoma demonstrating PPP1R17 staining. CD = Cushing's disease. H&E = hematoxylin and eosin.




Supplemental Fig S4. Correlation between ATACseq accessibility and gene expression. **A-B.** Comparison of chromatin accessibility (left panels) and gene expression (right panels) of NF-Y target genes *CALM1* and *SPCS2* in CD corticotrophs (tumor) versus adjacent normal corticotrophs. **C.** Comparison of chromatin accessibility (left panels) and gene expression (right panels) of SP1 target gene *SCIN* in CD corticotrophs (tumor) versus adjacent normal corticotrophs. CD = Cushing's disease.



A







B



Supplemental Fig S5. The novel lncRNA PPP1R17-203 is transcribed from an internal *PPP1R17* site. **A.** Long-range interactions predicted for PPP1R17-203. **B.** Predicted 3D structure of PPP1R17-203. Source: <https://bioinformaticslab.erc.monash.edu/linc2function>



Supplemental Fig S6 Endogenous PP2A agonists are not transcriptionally overexpressed in CD. UMAP projections demonstrating expression patterns of *PPME1* and *SET* in *POMC*-overexpressing CD adenoma cells. UMAP = uniform manifold approximation and projection. CD = Cushing's disease.



Supplemental Fig S8. EGFR is overexpressed in CD. Representative mIHC image of whole-mounted CD adenoma and adjacent normal gland (i) with corticotroph-specific POMC expression. (ii-iv) EGFR expression (green) was compared to POMC expression (red). Scale bar = 200 μ M.